DEXCOM CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline in Filed Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products during the specified class period [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors have until December 26, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices, which were not approved by the FDA [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing health risks to users who depend on them for accurate glucose readings [3]. - The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 device, downplayed the severity of issues with the G7, and faced increased regulatory scrutiny and potential legal repercussions as a result [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for more details [4].